Studies a gut bacteria gene in people with Parkinson's disease
Looks at a gut bacteria gene, csgA, in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease
Key facts
- Where
- Leiden, NetherlandsSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07175922, who can take part
Where in Netherlands
- Center for Human Drug ResearchLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vertero Therapeutics
- Trial code
- NCT07175922
- Record updated
- 19 August 2026
- Original description
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.Read full original descriptionShow less
Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.
Inclusion: Between 18-80 years of age at ICF signing (inclusive); A diagnosis of PD within 10 years from the time of ICF signing; Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment; All participants must understand and provide written informed consent prior to any study specific procedures; Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments.
Exclusion: Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator; Use of systemic antibiotics within 30 days prior to enrollment; Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance; Recent GI infection in the past 3 months if deemed clinically significant by the investigator; Any known current or past eating disorder if deemed clinically significant by the investigator.